Author(s): Mohammed F. Al-Owaidi, Monther F. Al Ameri

Email(s): ,

DOI: 10.52711/0974-360X.2023.00152   

Address: Mohammed F. Al-Owaidi, Monther F. Al Ameri
Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, 10002, Baghdad, Iraq.
*Corresponding Author

Published In:   Volume - 16,      Issue - 2,     Year - 2023

Globally, breast cancer accounted for approximately 700?000 deaths in 2020. Estrogen receptor alpha (ERa) is the primary pathway for breast cancer treatment. Tamoxifen (TAM) is the most extensively used drug for estrogen receptor (+) breast cancer. However, it is implicated in endometrial carcinoma, pulmonary thrombus, stroke, and breast cancer resistance. This research aims to overcome these issues in selectivity and side effects. The study was conducted in a new drug design using Structure Based Drug Design (SBDD) approach, molecular docking with ERa and then predicting their ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) profile. GOLD (Genetic Optimization for Ligand Docking, v.5.7.1), SwissADME and BIOVIA Discovery Studio Visualizer 2020 applications used for the predicting and analyzing of the results. It has shown that all of our compounds (MFA1-8) where a higher PLP (the Piecewise Linear Potential) fitness scores with a range (66.21-77.20) than (60.96) for TAM with different molecular interactions such as H- bondings and non-covalent hydrophobic interactions with the pose. They were all exhibited better conformation to prevent helix-12 (H-12) from repositioning over the opening of the binding pocket. This work generated fresh insight into the significant hydrophobic bonding with LEU428. MFA1-8 showed better pharmacokinetics, drug-likeness, and toxicity profiles than TAM. These findings suggest that these novel 3-chlorobenzo[b]thiophene-2-carbonyl chloride derivatives could serve as the lead compounds to fight breast cancer by inhibiting the ERa pathway.

Cite this article:
Mohammed F. Al-Owaidi, Monther F. Al Ameri. Docking Study, ADMET Profiling of the Designed 3-Chlorobenzo[b]thiophene-2-Carbonyl Chloride Derivatives: Promising Anti-Breast Cancer Activity. Research Journal of Pharmacy and Technology 2023; 16(2):901-7. doi: 10.52711/0974-360X.2023.00152

Mohammed F. Al-Owaidi, Monther F. Al Ameri. Docking Study, ADMET Profiling of the Designed 3-Chlorobenzo[b]thiophene-2-Carbonyl Chloride Derivatives: Promising Anti-Breast Cancer Activity. Research Journal of Pharmacy and Technology 2023; 16(2):901-7. doi: 10.52711/0974-360X.2023.00152   Available on:

1.    Akshay R. Yadav SKM. Cancer- A Silent Killer: An Overview. Asian J Pharm Res. 2020;10(3):213-6. DOI: 10.5958/2231-5691.2020.00036.2  
2.    Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49. DOI: 10.3322/caac.21660
3.    Golding BT. The story of rucaparib (rubraca). Successful Drug Discovery. 2019;4:201-23.
4.    Pushpa A. Karale MAK, Mokshada C. Utikar. Advanced Molecular Targeted Therapy in Breast Cancer. Res J Pharmacology and Pharmacodynamics. 2018;10(1):29-37. DOI: 10.5958/2321-5836.2018.00006.X
5.    Muchtaridi M, Syahidah HN, Subarnas A, Yusuf M, Bryant SD, Langer T. Molecular docking and 3D-pharmacophore modeling to study the interactions of chalcone derivatives with estrogen receptor alpha. Pharmaceuticals. 2017;10(4):81.
6.    Arjun Patidar SCS, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J Nur Edu & Research. 2012;2(1):28-32.
7.    Ravindra B. Saudagar NSD, Deepak S. Musmade , Vinayak M. Gaware, D. A. Jain. SERM’s in Treatment of Breast Cancer. Asian J Pharm Res. 2012;1(4):81-6.;PID=2011-1-4-1
8.    Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. Journal of Medicinal Chemistry. 2021;64(16):11841-56. DOI: 10.1021/acs.jmedchem.1c00847
9.    Bafna D, Ban F, Rennie PS, Singh K, Cherkasov A. Computer-aided ligand discovery for estrogen receptor alpha. International Journal of Molecular Sciences. 2020;21(12):4193.
10.    Borkar Sudarshan SV, Chatap Viveknand, Sawant Vilas, R Suresh, Dama Ganesh. Tamoxifen Citrate Loaded Solid Lipid Nanoparticles- A Novel Approach In The Treatment of ER+ Breast Cancer. Research J Pharma Dosage Forms and Tech 2009;1(2):143-9.
11.    Lu Y, Gutgesell LM, Xiong R, Zhao J, Li Y, Rosales CI, et al. Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer. Journal of medicinal chemistry. 2019;62(24):11301-23. DOI: 10.1021/acs.jmedchem.9b01580
12.    GK Sudhakar VP, Arvind Pai. An overview on current Strategies in Breast Cancer Therapy. Research J Pharmacology and Pharmacodynamics. 2013;5(6):353-5.
13.    Asaad RA. Hormone Receptor Status and its Relation to C-Reactive Protein and other Prognostic factors in Breast Cancer in Jableh- Syria. Research J Pharm and Tech. 2017;10(9):3003-10. DOI: 10.5958/0974-360X.2017.00532.7
14.    Ibrahim NW, Mahdi MF, Raauf AM. Design, molecular docking, synthesis and evaluation of new 5-aminoisatin derivatives as tyrosine kinase inhibitors. Materials Today: Proceedings. 2021.
15.    Kuhn D, Coates C, Daniel K, Chen D, Bhuiyan M, Kazi A, et al. Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci. 2004;9:2605-17. DOI: 10.2741/1420.
16.    Deepak Kumar Basedia BS, B. K. Dubey, Pankaj Sharma. Synthesis and Anticancer Activity of Novel Substituted 1,3,4-oxadiazolo-[3,2-a]-1,3,5-triazine and 1,3,4-thiadiazolo-[3,2-a]-1,3,5-triazine Derivatives. Asian J Research Chem. 2014;7(3):310-5.
17.    Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature structural biology. 2002;9(5):359-64. DOI: 10.1038/nsb787.
18.    Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Advances in protein chemistry and structural biology. 2019;116:135-70. DOI: 10.1016/bs.apcsb.2019.01.001.
19.    Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium. Endocrine reviews. 2018;39(5):664-75. DOI: 10.1210/er.2018-00087.
20.    V. N. Dange SJS, C.S. Magdum, S.K. Mohite. A Review on Breast cancer: An Overview. Asian J Pharm Res. 2017;7(1):49-51. DOI: 10.5958/2231-5691.2017.00008.9  
21.    Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Journal of Clinical Oncology. 1996;14(9):2584-9. DOI: 10.1200/JCO.1996.14.9.2584
22.    Bai C, Ren S, Wu S, Zhu M, Luo G, Xiang H. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer. European Journal of Medicinal Chemistry. 2021;221:113543. DOI: 10.1016/j.ejmech.2021.113543.
23.    Lu Y, Liu W. Selective estrogen receptor degraders (SERDs): A promising strategy for estrogen receptor positive endocrine-resistant breast cancer. Journal of Medicinal Chemistry. 2020;63(24):15094-114. DOI: 10.1021/acs.jmedchem.0c00913.
24.    Muchtaridi M, Dermawan D, Yusuf M. Molecular Docking, 3D Structure-Based Pharmacophore Modeling, and ADME Prediction of Alpha Mangostin and its Derivatives against Estrogen Receptor Alpha. Journal of Young Pharmacists. 2018;10((3. DOI:10.5530/jyp.2018.10.58.
25.    Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753-8. DOI: 10.1038/39645.
26.    Jackson LR, Cheung KL, Buzdar AU, Robertson JF. Arzoxifene: the evidence for its development in the management of breast cancer. Core Evidence. 2007;2(4):251.
27.    Y Maximov P, M Lee T, Craig Jordan V. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Current clinical pharmacology. 2013;8(2):135-55. DOI: 10.2174/1574884711308020006.
28.    Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast cancer research and treatment. 2020;180(3):635-46. DOI: 10.1007/s10549-020-05575-9.
29.    Tria GS, Abrams T, Baird J, Burks HE, Firestone B, Gaither LA, et al. Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer. Journal of medicinal chemistry. 2018;61(7):2837-64. DOI: 10.1021/acs.jmedchem.7b01682.
30.    P. Jaya Preethi KBS, K. Pavan Kumar, R. Rajavelu , T. Sivakumar. Synthesis, Characterization and Its Biological Evaluation of Some Novel 4-Thiazolidinone and 2-Azetidinone Derivatives. Asian J Pharm Res. 2012;2(2(.
31.    F Ghazi YA, Mahdi MF, Dawood AH. Theoretical Drug Design, Molecular Docking And ADME Study Of New 1, 3, 4-Oxadiazole Derivatives: Promising Anticancer Agents Against Both Breast And Lung Cancers. Egyptian Journal of Chemistry. 2021;64(11):5-6. DOI: 10.21608/EJCHEM.2021.75663.3735
32.    Wang Z, Li Y, Ai C, Wang Y. In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines. International journal of molecular sciences. 2010;11(9):3434-58. DOI: 10.3390/ijms11093434.
33.    Dykstra KD, Guo L, Birzin ET, Chan W, Yang YT, Hayes EC, et al. Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERα. Bioorganic & medicinal chemistry letters. 2007;17(8):2322-8. DOI: 10.1016/j.bmcl.2007.01.054.
34.    Pike A, Brzozowski A, Walton J, Hubbard R, Bonn T, Gustafsson J-Å, et al. Structural aspects of agonism and antagonism in the oestrogen receptor. Biochemical Society Transactions. 2000;28(4):396-400.
35.    Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA, et al. Molecular classification of estrogens. Cancer Research. 2001;61(18):6619-23.
36.    Bhanushali U, Kalekar-Joshi S, Kulkarni-Munshi R, Yellanki S, Medishetty R, Kulkarni P, et al. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1, 3, 4] oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2017;17(1):67-74. DOI: 10.2174/1871520615666160504094222.
37.    Tantray MA, Khan I, Hamid H, Alam MS, Dhulap A, Kalam A. Synthesis of benzimidazole-linked-1, 3, 4-oxadiazole carboxamides as GSK-3β inhibitors with in vivo antidepressant activity. Bioorganic chemistry. 2018;77:393-401. DOI: 10.1016/j.bioorg.2018.01.040.
38.    Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug discovery today: Technologies. 2004;1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007.
39.    Baell JB, Nissink JWM. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017 Utility and Limitations. ACS chemical biology. 2018;13(1):36-44.
40.    da Silva Júnior OS, Franco CdJP, de Moraes AAB, Cruz JN, da Costa KS, do Nascimento LD, et al. In silico analyses of toxicity of the major constituents of essential oils from two Ipomoea L. species. Toxicon. 2021;195:111-8. DOI: 10.1016/j.toxicon.2021.02.015.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available